S49076 is primarily investigated for its application in oncology, specifically as a potent and selective inhibitor of the AXL receptor tyrosine kinase. It demonstrates promising antitumor activity in preclinical models, particularly in cancers that exhibit resistance to targeted therapies or chemotherapy. By blocking AXL signaling, S49076 helps suppress tumor cell proliferation, invasion, and metastasis, while also modulating the tumor microenvironment to enhance immune response. Its application is especially relevant in non-small cell lung cancer, acute myeloid leukemia, and other solid tumors where AXL overexpression is linked to poor prognosis. Ongoing research explores its use in combination with immune checkpoint inhibitors and other anticancer agents to improve therapeutic outcomes.